Research and Development

Showing 15 posts of 9578 posts found.

biogen_austria_238

New head of R&D at Biogen

April 27, 2016 Research and Development Biogen, Pfizer, R&D, erhlers, michael, michael erhlers, research and development

Biogen (NASDAQ: BIIB) has announced the appointment of Dr Michael Ehlers as executive vice president, research and development. His role …

NICE backs BMS’ paclitaxel in ovarian cancer; drops Eli Lilly’s Gemzar, J&J’s Yondelis

April 27, 2016 Research and Development, Sales and Marketing BMS, Eli Lilly, J&J, JJ, NICE, ovarian cancer, regulation

The National Institute for Health and Care Excellence (NICE) has backed Bristol-Myers Squibb’s paclitaxel as a treatment for ovarian cancer. …
entresto

NICE gives green light to Novartis’s heart drug Entresto

April 27, 2016 Research and Development, Sales and Marketing Entresto, NHS, NICE, Novartis, benefit, heart failure, patients

NICE has published final guidance recommending heart failure drug Entresto (sacubritil/valsartan). The drug, developed by Novartis, has performed well in …
baxter

Baxter hikes 2016 earnings view driven by strong Q1 results

April 27, 2016 Research and Development, Sales and Marketing Baxalta, FY, Q1, baxter, earnings, outlook, results, revenue

Baxter International (NYSE: BAX) reported better-than-expected first-quarter profits and raised its earnings outlook for 2016. The company now sees earnings …
headquarters_3_web

Eli Lilly Q1 earnings miss estimates, ups FY view; shares drop 2%

April 27, 2016 Research and Development, Sales and Marketing Eli Lilly, FY, Q1, earnings, revenue, sales

Shares in US drugmaker Eli Lilly (NYSE: LLY) dropped to close down over 2% Tuesday after the company posted first-quarter …
abpi_reception

ABPI welcomes recommendations from NHS specialised services report

April 27, 2016 Research and Development, Sales and Marketing ABPI, NHS, NHS England, NICE, National Audit Office, report, specialised services

The ABPI has welcomed the findings of a National Audit Office report on the commission of specialised service by NHS …
shirelabsus

Shire to close Hampshire base and relocate jobs, say reports

April 27, 2016 Manufacturing and Production, Research and Development Jobs, Shire, close, factory, hampshire, loss, relocate

Shire is set to cease operations at its site in Basingstoke, Hampshire, by the end of next year and relocate …
ironwood_pharma

AstraZeneca sells US rights for gout treatment to Ironwood Pharmaceuticals

April 27, 2016 Research and Development, Sales and Marketing AstraZeneca, Ironwood, Licencing, Zurampic, agreement, exclusive, gout, lesinurad, sales

AstraZeneca (LSE: AZN) has entered into a licencing agreement with Ironwood Pharmaceuticals (NASDAQ: IRWD) which will see the latter granted …
novartis_outside_1

Novartis’ Ilaris gets US FDA breakthrough therapy designation to treat fever syndromes

April 27, 2016 Business Services, Research and Development Breakthrough Therapy Designation, Novartis, US FDA, periodic fever syndromes

Novartis (VTX: NOVN) on Wednesday said its drug to treat three rare types of periodic fever syndromes has been granted …
hawthorn_eisai

Eisai poaches senior Pfizer and Sanofi execs for neurology group

April 26, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Pfizer, Sanofi, appointments, hawthorne, zaim

Eisai has made new appointments to its US neurology business group, bringing in senior executives who have previously held positions …
george-freeman1

Northern Powerhouse life sciences contributing £10 billion to UK economy, says minister

April 26, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Jobs, Northern Powerhouse, contribution, economy, exporting, george freeman, investment, life sciences, minister, north

Minister for Life Sciences, George Freeman MP, has revealed that life sciences businesses within the Northern Powerhouse are contributing over …
clinicaltrial1

US panel says Sarepta’s trial DMD drug not proven effective

April 26, 2016 Manufacturing and Production, Research and Development DMD, US FDA, drug trial, sarepta

A US advisory committee has concluded Sarepta Therapeutics’ (Nasdaq: SRPT) trial drug to treat muscle wasting condition has not proved …
credit_bayerag

Bayer’s earnings beat estimates as blockbusters shine

April 26, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales

Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …
astrazeneca_building_white

AstraZeneca’s COPD therapy gets US FDA approval

April 26, 2016 Research and Development, Sales and Marketing AstraZeneca, COPD, US FDA, drug approval

UK drug firm AstraZeneca (LSE: AZN) said the US Food and Drug Administration has approved its therapy to treat chronic …
The Gateway to Local Adoption Series

Latest content